Merck applies for approval of its new insomnia drug suvorexant
Comments (0)Posts tagged: merck
Comments (0)
Merck Has Positive Results With New Insomnia Drug
Merck has announced positive results in a phase 3 trial of its insomnia drug. It's a key player in the companies up and coming products, especially considering the loss of patent protection on its top drugs for asthma and allergys. The experimental drug known as suvorexant, uses a new mechanism ...
Merck Serono enters development agreement with Threshold for hypoxia-targeted drug
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.
Merck selects Idera Pharmaceuticals’ TLR agonists for evaluation, use as vaccine adjuvant candidates
Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.
Drugmaker Merck to pay $24M to settle Medicaid case
Drugmaker Merck & Co. will pay Massachusetts $24 million to settle a civil lawsuit accusing a former subsidiary of causing the state to overpay pharmacists for a widely used asthma medication. Attorney General Martha Coakley said Tuesday that the deal with Merck and 12 other drugmakers who settled previously enables ...
Merck And The ADAP Crisis Task Force Announce New Agreement To Improve Access And Care For People With HIV
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the ADAP Crisis Task Force (ACTF) announced a number of new initiatives to help struggling state AIDS Drug Assistance Programs (ADAPs) continue to provide access to medicines to people living with HIV. This is the third major ...
Merck, PATH form partnership to fight causes of maternal mortality
Pharmaceutical company Merck (MSD) announced Monday it has "awarded a grant to PATH, a global health nonprofit, to identify game-changing technologies with the potential to save the lives of women during pregnancy and childbirth in low-resource settings," according to a Merck press release.
Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer
Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.
Dr. Luther T. Clark to present Merck Academy Talk at SUNY Downstate
Luther T. Clark, MD, FACC, will discuss preclinical drug discovery and development at SUNY Downstate Medical Center, Thursday, December 1, 2011. Dr. Clark's presentation will take place at 12:00 noon in the Health Science Education Building, Lecture Hall 1 A, 395 Lenox Road, Brooklyn, New York 11203. ...
Dr. Luther T. Clark to present Merck Academy Talk at SUNY Downstate
(SUNY Downstate Medical Center) Luther T. Clark, M.D., FACC, will discuss preclinical drug discovery and development at SUNY Downstate Medical Center, Thursday, Dec. 1, 2011. Dr. Clark's presentation will take place at 12 p.m. in the Health Science Education Building, Lecture Hall 1 A, 395 Lenox Road, Brooklyn, N.Y., 11203.
Merck agrees to pay $950 million in Vioxx settlement
The pharmaceutical giant will pay a $321 million criminal fine and a $628 million civil settlement.
Merck to Pay $950M to Settle Probe of Vioxx Marketing
By Steven Reinberg HealthDay Reporter TUESDAY, Nov. 22 (HealthDay News) -- The U.S. Justice Department said Tuesday that the drug company Merck will pay $950 million to resolve investigations into its marketing of the blockbuster painkiller Vioxx, which was pulled from the market ...